Design, synthesis and biological evaluation of Piperazinylanthranilamides as potential factor Xa inhibitors
作者:Atul N. Khadse、Hardik H. Savsani、Rupesh V. Chikhale、Rahul B. Ghuge、Dixit R. Prajapati、Goshiya Kureshi、Prashant R. Murumkar、Kirti V. Patel、Sadhana J. Rajput、Mange Ram Yadav
DOI:10.1016/j.molstruc.2022.133974
日期:2022.12
reported FXa inhibitors were retained, while substituted phenylpiperazinylamides were used as S4 binding ligands to improve the physicochemical properties of the resulting compounds. Compounds (6y and 7f) exhibited the most potent FXa inhibitory activities with IC50 values of 0.6 µM and 0.74 µM exhibiting high selectivity over thrombin. Both compounds displayed good anticoagulant activity in rats. Compound
直接抑制 FXa 已成为一种有效的策略,可以实现抗凝,维持正常止血,同时将出血风险降至最低。已经设计和合成了一系列新的邻氨基苯甲酰胺衍生物,其中邻氨基苯甲酰胺核心结构中 P1 和 P4 基序的羰基和氨基的键合顺序已被颠倒。为了提高对 FXa 的选择性,保留了已报道的 FXa 抑制剂中存在的卤代芳族基团,而取代的苯基哌嗪酰胺用作 S4 结合配体以改善所得化合物的物理化学性质。化合物 ( 6y和7f)表现出最有效的 FXa 抑制活性,IC 500.6 µM 和 0.74 µM 的值对凝血酶表现出高选择性。两种化合物在大鼠中均显示出良好的抗凝活性。化合物 ( 6y)在出血风险评估中显示出与标准药物利伐沙班相似的安全性。分子对接和分子动力学等模拟研究支持类似物与酶 FXa 的强结合